^
    Back
    Association details:
    Biomarker:CXCL10 expression
    Cancer:Bladder Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Pathol Oncol Res
    Title:

    Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy via interferon-alpha response in muscle-invasive bladder cancer

    Published date:
    04/04/2023
    Excerpt:
    Besides, both CXCL10 and LAMP3 expression in the tumor tissues indicated favorable OS in the training cohort (Figure 5D, p = 0.006, p = 0.001, respectively) and validation I cohort (Figure 5E, p = 0.029, p = 0.005, respectively).
    DOI:
    https://doi.org/10.3389/pore.2023.1611117